Despite a risk for severe side effects, pembrolizumab has a record of improving recurrence-free survival that makes it an ...

Teos and GSK were the last to report a new setback in TIGIT targeting for non-small cell lung cancer patients. Read why I am ...

Five-year data from the KEYNOTE-048 trial support the use of pembrolizumab and pembrolizumab-chemotherapy as standards of care, researchers wrote.

KaliVir Immunotherapeutics has concluded the first cohort in the Phase I/Ib STEALTH-001 trial evaluating VET3-TGI for ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical ...

The KEYNOTE-B96 study of pembrolizumab plus paclitaxel in recurrent platinum-resistant ovarian cancer has met its primary end point of progression-free survival.

Pembrolizumab (Keytruda) given before and after surgery to supplement adjuvant therapy improved responses and survival in patients with previously untreated, locally advanced head and neck ...

Adding pembrolizumab to standard-of-care treatment improved event-free survival (EFS) in locally advanced head and neck squamous cell carcinoma (HNSCC), according to new results of the KEYNOTE-689 ...

Patients treated with pembrolizumab plus paclitaxel with or without bevacizumab had a statistically significant and clinically meaningful improvement in PFS, regardless of PD-L1 status.

ATG-022 is Antengene's CLDN18.2 antibody-drug conjugate; KEYTRUDA® (pembrolizumab) is MSD's anti-PD-1 therapy. ATG-022 is uniquely positioned in the global landscape, with data supporting ...